Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis

Aims To evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF). Methods and results We reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset ≤7 days. We used a random-effects model to combine quantitative data and rated the quality of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation). From...